Chengdu Kangnuoxing Biopharma,inc.

This study is testing a new biologic drug called Stapokibart, given as a shot, for adults with moderate-to-severe atopic dermatitis (eczema). The trial will enroll 1000 people to see if the drug is safe and helps control the condition. It is an open-label study, meaning everyone …